Our study is the first to evaluate and demonstrate the efficacy of RO6839921, the IV prodrug of the MDM2 antagonist idasanutlin, as a single agent and in combination with temozolomide in 2 TP53 wt orthotopic models of neuroblastoma. Here, TP53 is linked to neuroblastoma.